Drugs / KD-019 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03854994 | Aug 2018 → Aug 2021 | B-cell acute lymphoblastic leukemia | Yan'an Affiliated Hospital of Kunming Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KD-019 CAR-T cells | “After the infusion, subjects will accept follow-up for side effects and effect of KD-019 CAR-T cells by the sponsor.” NCT03854994 ↗ |
| Modality | Cell therapy | “Autologous genetically modified anti-CD19 CAR transduced T cells” NCT03854994 ↗ |
| Route | Intravenous | “The CAR-T cells will be administered by i.v. injection over 20-30 minutes” NCT03854994 ↗ |